StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > AGM

<< Previous

Bullboard Posts

Next >>

Comment by davewhoon Jul 01, 2021 9:31am

226 Views

Post# 33478771

RE:RE:RE:RE:RE:AGM

Interesting number from the voting results

"Approximately 1.3% of shareholders opposed the motions."

which would mean 98.7% of SHAREHOLDERS who actually voted did vote in favour of the motions.

so that would seem to indicate that the 1.3% were a very small group of large shareholders

now who could that be?

SZLS hasn't filed the results on sedar yet. There could be more detailed numbers when they do. Last year the results were filed the following day. But since today is a holiday likely tomorrow.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity